Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ADPT vs MRNA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MRNA Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

MRNA Overall Winner 6-Pillar Tally: ADPT 3 – 3 MRNA Matrix Metrics: ADPT 4 – 6 MRNA

As of Nov 17, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over Adaptive Biotechnologies Corporation (ADPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, R&D & Supply-Chain Moat). ADPT carries a Unified Composite Score of 43.2/100 (HOLD) at $28.46 (N/M Forward P/E, -16.2% operating margin), whereas MRNA carries 46.6/100 (HOLD) at $206.00 (23.0x Forward P/E, -80.8% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ADPT vs MRNA
ADPT NASDAQ
Adaptive Biotechnologies Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$28.46
+2.12% 1D
Market Cap $4.7B
TTM Revenue $298M
Forward P/E N/M
Beta / 30D Vol 1.71β · 59% Vol
Unified Composite Score
43.2 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.6% over 20 days), RSI 55
RSI-14: 54.6 · SMA20: $27.46 · SMA50: $27.06
MRNA NASDAQ Head-to-Head Winner
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$206.00
-4.31% 1D
Market Cap $90.4B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.37β · 100% Vol
Unified Composite Score
46.6 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 44
RSI-14: 44.4 · SMA20: $228.09 · SMA50: $204.37

6-Pillar Scorecard Institutional Category Breakdown (ADPT 3 – 3 MRNA)

Columns: Metric · ADPT · MRNA
1. Valuation Multiples MRNA
Forward P/E N/M 23.0x
Trailing P/E N/M 23.0x
PEG Ratio N/M N/M
EV / Revenue 16.9x 37.0x
2. Growth & Scale MRNA
Revenue Growth (YoY) -10.7% +29.2%
Earnings Growth (YoY) -70.1% -85.1%
TTM Revenue (USD) $298M $2.52B
Market Cap $4.7B $90.4B
3. Profitability & Quality ADPT
Gross Margin 46.2% -42.0%
Operating Margin -16.2% -80.8%
Net Profit Margin -23.7% -110.5%
Return on Equity (ROE) -36.4% -34.5%
4. Balance Sheet & Cash Flow ADPT
Cash Generation (TTM) -$8.8M -$2.04B
Cash Flow Margin -3.0% -81.0%
Net Cash / Leverage $333M Net Debt (2.32x D/E) $3.03B Net Debt (0.62x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ADPT
Options Structure Phase BREAKOUT CONSOLIDATION
Current IV / %ile 78.0% (36th %ile) 100.2% (64th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) 1.29x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 62.4% of Rev ($186M) 38.8% of Rev ($980M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ADPT (4) vs MRNA (6)
Institutional Metric ADPT MRNA Criterion Row Edge
Market Capitalization
Scale
$4.7B $90.4B Larger Scale MRNA
Trailing P/E Ratio
Valuation
N/M 23.0x Lower Multiple MRNA
Forward P/E Ratio
Valuation
N/M 23.0x Lower Multiple MRNA
Revenue Growth (YoY)
Growth
-10.7% +29.2% Higher Growth MRNA
Operating Margin (TTM)
Profitability
-16.2% -80.8% Higher Margin ADPT
Net Profit Margin
Profitability
-23.7% -110.5% Higher Margin ADPT
Return on Equity (ROE)
Capital Efficiency
-36.4% -34.5% Higher ROE MRNA
52-Week Range Position
Momentum
81% ($12–$32) 71% ($22–$281) Stronger Trend ADPT
Beta / 30D Volatility
Risk Regime
1.71β · 59% Vol 2.37β · 100% Vol Lower Realized Risk ADPT
Unified Institutional Score
Composite Signal
43.2 / 100 (HOLD) 46.6 / 100 (HOLD) Higher Composite MRNA
Trailing 12M Revenue (USD)
Operating Scale
$298M $2.52B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.2% -42.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 16.9x EV/Rev N/M PEG · 37.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$8.8M ($333M Net Debt (2.32x D/E)) -$2.04B ($3.03B Net Debt (0.62x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ADPT +28.04 pp
ADPT: +18.83% · MRNA: -9.21%
3M Horizon MRNA +6.48 pp
ADPT: +11.65% · MRNA: +18.13%
6M Horizon MRNA +230.97 pp
ADPT: +119.6% · MRNA: +350.57%
1Y Horizon MRNA +629.81 pp
ADPT: +101.84% · MRNA: +731.65%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ADPT Revenue MRNA Revenue ADPT Op. Margin MRNA Op. Margin Margin Leader
FY2018 $60M $140M -89.4% -306.0% ADPT
FY2019 $90M $60M -92.1% -906.8% ADPT
FY2020 $100M $800M -155.3% -95.0% MRNA
FY2021 $150M $18.5B -135.4% 72.0% MRNA
FY2022 $190M $19.3B -108.0% 48.9% MRNA
FY2023 $170M $6.85B -133.3% -61.9% MRNA
FY2024 $180M $3.24B -90.8% -121.9% ADPT
FY2025 $280M $1.94B -20.6% -158.1% ADPT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ADPT BREAKOUT
70d in phase · OBV ACCUMULATION
Current IV 78.0%
IV Percentile 36th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ADPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
19d in phase · OBV NEUTRAL
Current IV 100.2%
IV Percentile 64th %ile
Put/Call OI Skew 1.29x (Put-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $215.27 · IV 83.7%

MRNA Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($21,527)

Compare $21,527 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 83.7% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq A

Dec 18 $190P / $220-$260C Seagull

Sell 1x $190P · Buy 1x $220/$260C · 32d

Net Entry $140 Debit
T+5d @ +5% Move +$693 (+23.1% RoM)
Max Risk / Buffer -11.7% Put Cushion ($3,005 Mgn)
5d Edge & Liquidity 1.1x R:R · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ADPT Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $4.7B market capitalization and -16.2% operating margin.
OpEx & R&D Reinvestment 62.4% of Rev ($186M)
90D Engineering Disclosures 0 Published
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $90.4B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics

Investor FAQ ADPT vs MRNA Key Questions & Quantitative Answers

As of Nov 17, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over Adaptive Biotechnologies Corporation (ADPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, R&D & Supply-Chain Moat). ADPT carries a Unified Composite Score of 43.2/100 (HOLD) at $28.46 (N/M Forward P/E, -16.2% operating margin), whereas MRNA carries 46.6/100 (HOLD) at $206.00 (23.0x Forward P/E, -80.8% operating margin). Technically, ADPT sits in a Markup phase (RSI 54.6, BREAKOUT options structure) and MRNA sits in a Neutral phase (RSI 44.4, CONSOLIDATION options structure).

MRNA leads the Growth & Scale pillar: ADPT posts -10.7% YoY revenue growth and -70.1% YoY earnings growth on $298M TTM revenue (46.2% gross margin, -16.2% operating margin), compared with MRNA at +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ADPT cumulative revenue shifted +366.7% while MRNA shifted +1285.7%. In operating R&D and SG&A reinvestment, ADPT deploys 62.4% of Rev ($186M) (0 90-day corporate R&D disclosures) versus 38.8% of Rev ($980M) (0 disclosures) for MRNA.

MRNA screens cheaper on headline valuation multiples. ADPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.9x EV/Revenue (-3.0% FCF margin), whereas MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 37.0x EV/Revenue (-81.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADPT (-36.4% ROE) versus MRNA (-34.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ADPT carries 78.0% implied volatility (36th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.71β · 59% Vol realized risk). By comparison, MRNA carries 100.2% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 1.29x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.37β · 100% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.